Abstract
DCK catalyzes the intracellular phosphorylation of fludarabine. The promoter and coding region of the DCK gene were analyzed in 74 follicular lymphoma (FL) patients receiving a therapeutic regimen that included fludarabine. DCK mRNA expression was quantified in a cohort of healthy donors. Four previously described genotypic variants, -360C>G, -201C>T (rs2306744), C28624T (rs11544786) and c.91+37G>C (rs9997790), as well as the new variant, -12C>G, were identified. Variant C28624T showed a lower risk of lymphopenia (P=0.04), but a higher risk of neutropenia (P=0.04). Statistical significance was found in bivariate logistic regression between lymphopenia and infectious episodes in the induction period (odds ratio 3.85, P=0.04).
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alleles
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cohort Studies
-
DNA Mutational Analysis
-
Deoxycytidine Kinase / genetics*
-
Drug-Related Side Effects and Adverse Reactions / genetics
-
Gene Expression Regulation, Enzymologic
-
Gene Expression Regulation, Leukemic
-
Gene Frequency
-
Genotype
-
Humans
-
Kaplan-Meier Estimate
-
Logistic Models
-
Lymphoma, Follicular / drug therapy
-
Lymphoma, Follicular / genetics*
-
Lymphopenia / chemically induced
-
Neutropenia / chemically induced
-
Polymorphism, Single Nucleotide*
-
Promoter Regions, Genetic / genetics
-
Reverse Transcriptase Polymerase Chain Reaction
-
Treatment Outcome
-
Vidarabine / administration & dosage
-
Vidarabine / adverse effects
-
Vidarabine / analogs & derivatives
Substances
-
Deoxycytidine Kinase
-
Vidarabine
-
fludarabine